On May 21, 2026 Orion Pharma (Orion Corporation) reported that for the first time it will present clinical data from the ongoing Phase 1/2 TEADES trial evaluating ODM-212, an investigational oral small-molecule pan-TEAD inhibitor, at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, USA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The TEADES study is a multi-center, open-label, first-in-human trial designed to evaluate the safety, tolerability and preliminary anti-tumour activity of ODM-212 in patients with advanced solid tumours, including tumour types characterized by dysregulation of the Hippo pathway, such as mesothelioma and epithelioid hemangioendothelioma (EHE).
Details of the presentation are as follows:
Title: First-in-human trial of the TEAD inhibitor ODM-212 in patients with advanced solid tumours (TEADES)
Session: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology (Hall A)
Abstract number: 3111
Presentation date/time: May 30, 2026, 1:30 – 4:30 PM CDT
Data from the phase 1 study will be presented during the conference.
"The upcoming presentation at ASCO (Free ASCO Whitepaper) marks an important milestone for ODM-212, our clinical-stage TEAD inhibitor," says professor Outi Vaarala, Executive Vice President, Research & Development, Orion Pharma. "We look forward to sharing initial data from the TEADES study, which will inform the ongoing development of ODM-212 for patients with advanced solid tumours with high unmet medical need."
About the TEADES study
The TEADES trial is a Phase 1/2 multi-center, open-label study that will enroll up to 300 patients with MPM, EHE or other solid tumours with dysfunction of the Hippo pathway. The trial includes patients who have progressed despite available standard treatmentsand with limited further treatment options. The primary endpoints of the study are safety and tolerability with secondary endpoints including Overall Response Rate, Progression Free Survival and Overall Survival. This is a global trial conducted at leading oncology centers in the US and Europe.
About ODM-212
ODM-212 is an oral small-molecule pan-TEAD (Transcriptional Enhanced Associate Domain) inhibitor developed by Orion Pharma. It targets the Hippo signaling pathway, which regulates cell growth and organ size. Dysregulation of this pathway,particularly through YAP/TAZ activation,can lead to uncontrolled tumour growth and resistance to cancer therapies. ODM-212 works by blocking TEAD transcription factors, disrupting YAP-TEAD protein-protein interactions, and inhibiting TEAD auto-palmitoylation, which is essential for TEAD activity.
(Press release, Orion, MAY 21, 2026, View Source [SID1234665947])